These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20073406)

  • 1. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
    Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
    J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
    Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2000 Feb; 58(1-2):143-52. PubMed ID: 10669065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
    Balhara YPS; Singh S; Sarkar S
    Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
    D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
    Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
    Sullivan JG; Webster L
    Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
    Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.